Cerus Corp (Cerus) is a biomedical company focused on blood safety. It develops and commercializes the INTERCEPT Blood System and pathogen-reduced blood components designed to improve the safety of transfusions. Cerus operates in a single reportable segment: blood safety.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cerus is engaged in various R&D initiatives, including maintaining compliance with regulatory requirements, obtaining potential PMA supplements for platelet and plasma systems, and pursuing FDA approval for the red blood cell system. The company is also involved in the development of a lyophilized IFC in collaboration with the DoD, and enhancements to its illumination device and INTERCEPT Blood System kits. Additionally, Cerus Corp is working on new product development and addressing regulatory requirements in different geographies. The R&D unit of Cerus Corp is responsible for managing scientific and regulatory personnel, conducting clinical and nonclinical studies, and overseeing the development of new products and enhancements. The unit also handles compliance with regulatory requirements and manages collaborations with government entities like BARDA and the DoD. In FY2025, the company spent US$67.7 million on its R&D, which as a percentage of revenue, stood at 28.9% and declined 14.9% YoY. As of December 2025, Cerus owns 21 issued or allowed US patents and approximately 154 issued or allowed foreign patents related to the INTERCEPT Blood System.